Interestingly, the tendency to decrease hepatic expression of Cd36 and Fabp4 found in response to MI supplementation suggests that this multi-ingredient treatment would tackle NAFLD by reducing FFA uptake into the liver. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.